Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults

被引:30
|
作者
Vasilescu, Iulia-Magdalena [1 ,2 ]
Chifiriuc, Mariana-Carmen [1 ,3 ,4 ]
Pircalabioru, Gratiela Gradisteanu [3 ]
Filip, Roxana [5 ,6 ]
Bolocan, Alexandra [5 ,7 ]
Lazar, Veronica [1 ]
Ditu, Lia-Mara [1 ]
Bleotu, Coralia [1 ,3 ,8 ]
机构
[1] Univ Bucharest, Dept Microbiol, Fac Biol, Bucharest, Romania
[2] INBI Prof Dr Matei Bals Natl Inst Infect Dis, Bucharest, Romania
[3] Univ Bucharest, Res Inst, Bucharest, Romania
[4] Romanian Acad, Bucharest, Romania
[5] Stefan Cel Mare Univ Suceava, Fac Med & Biol Sci, Suceava, Romania
[6] Reg Cty Emergency Hosp, Suceava, Romania
[7] Carol Davila Univ Med & Pharm, Univ Emergency Hosp, Dept Gen Surg, Bucharest, Romania
[8] Romanian Acad, Stefan S Nicolau Inst Virol, Bucharest, Romania
关键词
Clostridium difficile infection; gut microbiota; dysbiosis; biotics; fecal microbiota transplantation; INTESTINAL MICROBIOTA; NECROTIZING ENTEROCOLITIS; ASYMPTOMATIC COLONIZATION; RISK-FACTORS; BILE-ACIDS; DIVERSITY; TRANSPLANTATION; FIDAXOMICIN; PREVENTION; RESISTANCE;
D O I
10.3389/fmicb.2021.651081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this review, we focus on gut microbiota profiles in infants and adults colonized (CDC) or infected (CDI) with Clostridioides difficile. After a short update on CDI epidemiology and pathology, we present the gut dysbiosis profiles associated with CDI in adults and infants, as well as the role of dysbiosis in C. difficile spores germination and multiplication. Both molecular and culturomic studies agree on a significant decrease of gut microbiota diversity and resilience in CDI, depletion of Firmicutes, Bacteroidetes, and Actinobacteria phyla and a high abundance of Proteobacteria, associated with low butyrogenic and high lactic acid-bacteria levels. In symptomatic cases, microbiota deviations are associated with high levels of inflammatory markers, such as calprotectin. In infants, colonization with Bifidobacteria that trigger a local anti-inflammatory response and abundance of Ruminococcus, together with lack of receptors for clostridial toxins and immunological factors (e.g., C. difficile toxins neutralizing antibodies) might explain the lack of clinical symptoms. Gut dysbiosis amelioration through administration of "biotics" or non-toxigenic C. difficile preparations and fecal microbiota transplantation proved to be very useful for the management of CDI.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Treatment of Clostridioides difficile Infection
    Sehgal, Kanika
    Cifu, Adam S.
    Khanna, Sahil
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (09): : 881 - 882
  • [32] Management of Clostridioides difficile Infection
    Clarkin, Christina
    Quist, Stephanie
    Shamis, Renata
    King, Amber E.
    Shah, Bhavik M.
    CRITICAL CARE NURSE, 2019, 39 (05) : E1 - E12
  • [33] Treatment of Clostridioides difficile Infection
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1632): : 137 - 141
  • [34] Gut Microbiota-Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy
    Gurung, Bijay
    Stricklin, Maranda
    Wang, Shaohua
    METABOLITES, 2024, 14 (01)
  • [35] Editorial: Clostridioides difficile infection
    Granata, Guido
    Barbut, Frederic
    Petrosillo, Nicola
    FRONTIERS IN MEDICINE, 2024, 11
  • [36] Extraintestinal Clostridioides difficile infection
    Zhao, Hai
    Zhen, Lei Peng
    Ma, Juan
    Fan, Yang
    Cang, Jin Rong
    Liang, Jing Yao
    Zhang, Li Xia
    IDCASES, 2020, 22
  • [37] Intestinal Dysbiosis and Risk of Posttransplant Clostridioides difficile Infection in a Longitudinal Cohort of Liver Transplant Recipients
    Gomez-Simmonds, Angela
    Annavajhala, Medini K.
    Nunez, Maria Patricia
    Macesic, Nenad
    Park, Heekuk
    Uhlemann, Anne-Catrin
    MSPHERE, 2022, 7 (05)
  • [38] Global trends in gut microbiota and clostridioides difficile infection research: A visualized study
    Li, Zitong
    Ke, Haoran
    Lin, Qianyun
    Shen, Zefeng
    Chen, Ye
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (07) : 806 - 815
  • [39] Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
    Sahrmann, John M.
    Olsen, Margaret A.
    Keller, Matthew R.
    Yu, Holly
    Dubberke, Erik R.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
  • [40] Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection
    Yu, Si
    Ge, Xiaomeng
    Xu, Hui
    Tan, Bei
    Tian, Bowen
    Shi, Yujie
    Dai, Yimin
    Li, Yue
    Hu, Songnian
    Qian, Jiaming
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13